Metojectpen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate production. This limits synthesis of DNA, RNA and proteins in rapidly dividing cells, which curtails cancer cell proliferation. In rheumatic diseases, it also raises extracellular adenosine levels, providing anti‑inflammatory effects.

The exact dose of Metojectpen is individualized by the prescribing clinician based on the patient’s disease severity, weight, renal and hepatic function, and response to therapy. Dosing regimens vary between rheumatologic and oncologic indications, and the prescriber will set the appropriate schedule.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be stopped well before conception. Breastfeeding is also not recommended, as methotrexate can be excreted in milk and affect the infant.

To request Metojectpen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Metojectpen (methotrexate) is a conventional synthetic DMARD, offering oral‑like convenience in an injectable pen and a well‑established safety profile. Biologic DMARDs target specific cytokines (e.g., TNF‑α inhibitors) and may be used when methotrexate alone is insufficient, but they are generally more expensive and require more intensive monitoring.

Metojectpen should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the pen. If the product must be transported, maintain the cold chain using validated insulated containers and temperature monitors to preserve drug stability.

Metojectpen is a pre‑filled pen designed for subcutaneous injection. The prescriber or trained healthcare professional selects the prescribed dose, cleans the injection site, and presses the pen to deliver the medication into the subcutaneous tissue, typically in the abdomen or thigh.

The most serious risks include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, and profound bone‑marrow suppression that can lead to life‑threatening infections, anemia or bleeding. Patients should be monitored regularly for liver enzymes, lung symptoms and complete blood counts.

Metojectpen is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for those with active infections, immunodeficiency, or a history of pulmonary disease.